Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 1/20 | 0.42 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.42 |
| ▸ | RELA | Q04206 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.36 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5600769 | 0.89 | DDB1 (0.45) | DDB1CRBNNFKB1NFKB2RELA | |
| SCHEMBL30675273 | 0.89 | DDB1 (0.45) | DDB1CRBNNFKB1NFKB2RELA | |
| SCHEMBL3669232 | 0.79 | EPHX1 (0.47) | SMN1; SMN2EPHX1RAB9ALMNACA1 | |
| SCHEMBL16752660 | 0.79 | GAA (0.48) | SMN1; SMN2EPHX1EPHX2RAB9AALDH1A1 | |
| SCHEMBL17822020 | 0.78 | GAA (0.50) | SMN1; SMN2EPHX1EPHX2RAB9AALDH1A1 | |
| SCHEMBL3670657 | 0.78 | EPHX2 (0.51) | SMN1; SMN2EPHX2RAB9AALDH1A1LMNA | |
| SCHEMBL22083903 | 0.78 | KIF11 (0.41) | NFKB1NFKB2RELACYP3A4SMN1; SMN2 | |
| SCHEMBL7572544 | 0.77 | DDB1 (0.47) | DDB1CRBNNFKB1NFKB2RELA | |
| SCHEMBL17822068 | 0.77 | KDM4E (0.52) | SMN1; SMN2EPHX1EPHX2RAB9AALDH1A1 | |
| SCHEMBL1068979 | 0.76 | CARM1 (0.49) | DDB1CRBNSMN1; SMN2EPHX1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10196344-B2 | Glaucocalyxin a derivative and preparation method and application thereof | SUZHOU PHARMAVAN CANCER RESEARCH CENTER CO., LTD. (CN) | 2019-02-05 | — | — | US | claimed |
| US-20180079711-A1 | GLAUCOCALYXIN A DERIVATIVE AND PREPARATION METHOD AND APPLICATION THEREOF | SUZHOU PHARMAVAN CO., LTD (CN) | 2018-03-22 | — | — | US | claimed |
| EP-3275859-A1 | GLAUCOCALYXIN A DERIVATIVE AND PREPARATION METHOD AND APPLICATION THEREOF | Suzhou Pharmavan Cancer Research Center Co., Ltd. (CN) | 2018-01-31 | — | — | EP | claimed |
| CN-119585241-A | AT2R antagonists and uses thereof | 伊莱利利公司 | 2025-03-07 | — | — | CN | disclosed |
| US-20250074875-A1 | AT2R ANTAGONISTS AND USES THEREOF | ELI LILLY AND COMPANY | 2025-03-06 | — | — | US | disclosed |
| US-12122750-B2 | AT2R antagonists and uses thereof | ELI LILLY AND COMPANY (US) | 2024-10-22 | — | — | US | disclosed |
| WO-2023224853-A1 | AT2R ANTAGONISTS AND USES THEREOF | ELI LILLY AND COMPANY (US) | 2023-11-23 | — | — | WO | disclosed |
| US-20230373919-A1 | AT2R ANTAGONISTS AND USES THEREOF | ELI LILLY AND COMPANY | 2023-11-23 | — | — | US | disclosed |
| US-20230373919-A1 | AT2R ANTAGONISTS AND USES THEREOF | ELI LILLY AND COMPANY | 2023-11-23 | — | — | US | disclosed |
| US-20230373919-A1 | AT2R ANTAGONISTS AND USES THEREOF | ELI LILLY AND COMPANY | 2023-11-23 | — | — | US | disclosed |
| WO-2023224853-A1 | AT2R ANTAGONISTS AND USES THEREOF | ELI LILLY AND COMPANY (US) | 2023-11-23 | — | — | WO | disclosed |
| US-20180079711-A1 | GLAUCOCALYXIN A DERIVATIVE AND PREPARATION METHOD AND APPLICATION THEREOF | SUZHOU PHARMAVAN CO., LTD (CN) | 2018-03-22 | — | — | US | disclosed |
| US-20180079711-A1 | GLAUCOCALYXIN A DERIVATIVE AND PREPARATION METHOD AND APPLICATION THEREOF | SUZHOU PHARMAVAN CO., LTD (CN) | 2018-03-22 | — | — | US | disclosed |
| US-20180079711-A1 | GLAUCOCALYXIN A DERIVATIVE AND PREPARATION METHOD AND APPLICATION THEREOF | SUZHOU PHARMAVAN CO., LTD (CN) | 2018-03-22 | — | — | US | disclosed |
| EP-3275859-A1 | GLAUCOCALYXIN A DERIVATIVE AND PREPARATION METHOD AND APPLICATION THEREOF | Suzhou Pharmavan Cancer Research Center Co., Ltd. (CN) | 2018-01-31 | — | — | EP | disclosed |
| CN-104761460-B | Glaucocalyxin A derivative and preparation method and application thereof | 苏州沪云肿瘤研究中心股份有限公司 | 2017-06-20 | — | — | CN | disclosed |
| US-9487494-B2 | Cyclic hydrocarbon compounds for the treatment of diseases | LEO PHARMA A/S (DK) | 2016-11-08 | — | — | US | disclosed |
| US-20100317582-A1 | NOVEL CYCLIC HYDROCARBON COMPOUNDS FOR THE TREATMENT OF DISEASES | LEO PHARMA A/S (DK) | 2010-12-16 | — | — | US | disclosed |
| EP-2234961-A2 | NOVEL CYCLIC HYDROCARBON COMPOUNDS FOR THE TREATMENT OF DISEASES | LEO PHARMA A/S (DK) | 2010-10-06 | — | — | EP | disclosed |
| WO-2009065406-A2 | NOVEL CYCLIC HYDROCARBON COMPOUNDS FOR THE TREATMENT OF DISEASES | LEO PHARMA A/S (DK) | 2009-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317582-A1 | NOVEL CYCLIC HYDROCARBON COMPOUNDS FOR THE TREATMENT OF DISEASES | ARNT, AHR, CYP27A1 | DDB1 1897/4885CRBN 1344/4885NFKB1 756/4885 |
| US-20180079711-A1 | GLAUCOCALYXIN A DERIVATIVE AND PREPARATION METHOD AND APPLICATION THEREOF | SSB, GYPA, PEX14 | DDB1 3237/4885CRBN 3744/4885NFKB1 1359/4885 |
| US-20230373919-A1 | AT2R ANTAGONISTS AND USES THEREOF | AGTR2, AGTR1, AVPR2 | DDB1 4531/4885CRBN 4685/4885NFKB1 2206/4885 |
| US-10196344-B2 | Glaucocalyxin a derivative and preparation method and application thereof | SSB, GYPA, PEX14 | DDB1 3237/4885CRBN 3744/4885NFKB1 1359/4885 |
| US-20250074875-A1 | AT2R ANTAGONISTS AND USES THEREOF | AGTR2, AGTR1, AVPR2 | DDB1 4530/4885CRBN 4678/4885NFKB1 2170/4885 |
| US-12122750-B2 | AT2R antagonists and uses thereof | AGTR2, AGTR1, AVPR2 | DDB1 4531/4885CRBN 4685/4885NFKB1 2206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.